Komori
Semiannual Report4598Delta-Fly Pharma,Inc.Pharmaceuticals

Semiannual Report — FY2026 H1

What Delta-Fly Pharma,Inc. reported for the period from 2026-04-01 to 2027-03-31. Filed by DeltaーFly Pharma株式会社

How much it says
45Typical
What moved here
7named for the first time
Its own wording
29terms
Which filing this is
27/ 27newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the interim accounting period (1 April to 30 September 2026), the company generated no business revenue and recorded an operating loss, ordinary loss and interim net loss due primarily to research and development expenses. In addition, stated capital and capital surplus increased through the exercise of stock acquisition rights with adjustment provisions for the exercise price, while cash and cash equivalents also increased from the beginning of the period.

Komori's summary of this document, not the document's own words.
45Typical
How much this filing saysA weighted roll-up of 9 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 33 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
61
Detailed
Magnitude of change
30
Thin
Strategic shift
33
Thin
Capital movement
50
Typical
Disclosure gaps
68
Detailed
Risk changes
55
Typical
Finance and capital policy
53
Typical
Product portfolio
35
Thin
Technology position
10
Almost nothing
Confidence in strategic bets
R&D spend7億円Money spent making new things.
Cash left over-7億円Cash from the business, less what went into equipment.
Spent on equipmentNot disclosedThis document does not carry the figure.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
Delta-Fly Pharma,Inc. — FY2026 H1 | Komori